| Raynaud phenomenon | α-Adrenergic blockers |
| Angiotensin-II receptor blockers |
| Long-acting calcium channel blockers (dihydropyridines) |
| Pentoxifylline (Trental) |
| Stellate ganglionic blockades, digital sympathectomy |
| Skin fibrosis | Immunomodulatory drugs (d-penicillamine [Cuprimine], mycophenolate mofetil [Cellcept], cyclophosphamide [Cytoxan]) |
| Gastroesophageal reflux disease | Antacids |
| Histamine H2 Blockers |
| Proton pump inhibitors |
| Intestinal dysmotility or bacterial overgrowth | Antibiotics |
| Correction of nutritional deficiencies |
| Promotility agents |
| Pulmonary fibrosis or alveolitis | Immunomodulatory drugs |
| Initial therapy with oral or intravenous cyclophosphamide |
| Maintenance therapy with azathioprine (Imuran) |
| Pulmonary arterial hypertension | Diuretics |
| Endothelin-1 receptor inhibitors (bosentan [Tracleer]) |
| Oxygen |
| Phosphodiesterase-5 inhibitors (sildenafil [Revatio]) |
| Prostacyclin analogues (epoprostenol [Flolan], treprostinil [Remodulin], iloprost [Ventavis]) |
| Warfarin (Coumadin) is sometimes used in patients with recurrent pulmonary thromboembolic disease secondary to pulmonary arterial hypertension |
| Scleroderma renal crisis | Dialysis |
| Short-acting angiotensin-converting enzyme inhibitors |